MD-76 Drug Patent Profile
✉ Email this page to a colleague
When do Md-76 patents expire, and what generic alternatives are available?
Md-76 is a drug marketed by Mallinckrodt and Liebel-flarsheim and is included in two NDAs.
The generic ingredient in MD-76 is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Md-76
A generic version of MD-76 was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MD-76?
- What are the global sales for MD-76?
- What is Average Wholesale Price for MD-76?
Summary for MD-76
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | MD-76 at DailyMed |
US Patents and Regulatory Information for MD-76
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | MD-76 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 087073-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Liebel-flarsheim | MD-76R | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 019292-001 | Sep 29, 1989 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
